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Abstract
We have previously described two genes, ORFF and ORFG, from the LD1 locus near one telomere of chromosome
35, which are frequently amplified in Leishmania isolates. In Leishmania dono6ani LSB-51.1, gene conversion of the
rRNA gene locus on chromosome 27 with these two genes resulted in their over-expression, because of their
transcription by the RNA polymerase I-mediated rRNA promoter. The predicted ORFG protein has substantial
sequence homology to the ESAG10 gene product from the Trypanosoma brucei VSG expression site and both are
putative membrane proteins. Using successive rounds of gene replacement of the three ORFG genes in L. dono6ani
LSB-51.1, ORFG null mutants were obtained. These mutant cell lines show a direct relationship between ORFG
mRNA, protein expression levels and active transport of biopterin into the cells. Transformation of the null mutant
with a plasmid containing ORFG restores biopterin transport activity. In addition, the null mutants are unable to
grow in the absence of supplemental biopterin. Thus, ORFG encodes a biopterin transporter and has been renamed
BT1. © 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Leishmania are protozoan parasites that are
responsible for substantial public health prob-
lems, especially in tropical and subtropical re-
gions. The various species of Leishmania cause
disease ranging from localized cutaneous lesions
to disseminated visceral disease. Worldwide, over
Abbre6iations: BT1, biopterin transporter 1; EDTA,
ethylenediamine tetraacetic acid; HPLC, high pressure liquid
chromatography; ORF, open reading frame; PCR, polymerase
chain reaction; PTR1, pteridine reductase.
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20 million people are estimated to suffer from
leishmaniasis and 400 000 new cases occur each
year [1]. Visceral leishmaniasis is currently treated
with pentavalent antimonials, pentamidine and
amphotericin B, but these drugs are difficult to
administer and have considerable toxicity [1]. In
addition, resistance to therapy is common. Thus,
there is an urgent need for new therapeutic
approaches.
The genome of Leishmania has substantial plas-
ticity, with different strains containing amplified
circular or linear DNAs that vary in size and copy
number. Several of these amplified DNAs have
been shown to contain genes responsible for resis-
tance to drugs such as methotrexate, tunicamycin,
arsenite, DL-a-difluoromethylornithine and my-
cophenolic acid (for reviews, see Refs. [2–5]).
However, amplified DNA elements not obviously
associated with drug resistance have also been
identified, including circular D DNA in Leishma-
nia tropica [6], T DNA in Leishmania tarentolae
[7], and LD1:CD1 in several species of Leishmania
[8–10]. The sequences found in circular LD1 also
occurred in linear small chromosomes that were
amplified in L. tarentolae following nutrient stress
[11].
The multigenic LD1 locus is located near one
telomere on chromosome 35 of Leishmania and
various portions are amplified as 100–200 copies
of 55-kb circular molecules or 20–60 copies of
200–450-kb linear chromosomes in 15% of
Leishmania isolates tested [10,12,13]. We cloned
and sequenced the circular LD1 molecule from
one strain of Leishmania dono6ani (LSB-7.1), and
described several open reading frames (ORFs)
with potential protein-coding function [14–16]. In
another strain of L. dono6ani (LSB-51.1), gene
conversion resulted in duplication of two LD1
genes (ORFF and ORFG) into the rRNA gene
locus on chromosome 27 and their consequent
transcription by RNA polymerase I initiated at
the rRNA promoter [17]. Steady state mRNA
levels of both the ORFF and ORFG genes are
substantially elevated in this strain, and increased
ORFF protein levels were found [17].
The predicted ORFG protein has substantial
sequence homology to ESAG10, which occurs in
some Trypanosoma brucei VSG expression sites.
Both contain 12 putative membrane-spanning do-
mains that are predicted to form amphiphilic a-
helix or b-strands typical of type IV integral
membrane proteins [16]. Thus, it has been sug-
gested that these proteins are involved in the
formation of aqueous channels through the para-
site membrane, and are potentially transporters
[16]. Transfection with cosmids derived from the
L. dono6ani LD1 region, and plasmids expressing
only ORFG, rescued a methotrexate-resistant fo-
late-transport mutant of L. dono6ani (Moore and
Beverley, abstract 107, Woods Hole Molecular
Parasitology Meeting, 1996). These transfectant
cell lines showed elevated uptake of both
biopterin and folate, suggesting that ORFG (re-
named BT1) encodes a biopterin:folate trans-
porter. Subsequent studies expressing BT1 mRNA
in Xenopus oocytes confirmed that BT1 encodes a
biopterin transporter (Cunningham et al., abstract
236, Woods Hole Molecular Parasitology Meet-
ing, 1997). In this paper, we report the disruption
of the three BT1 genes in L. dono6ani LSB-51.1 by
successive rounds of gene replacement and gene
rescue with a plasmid construct containing BT1.
Using these mutant cell lines, we show a direct
relationship between BT1 mRNA, protein expres-
sion levels, and active transport of biopterin into
the cells. Null mutants of BT1 are unable to grow
as promastigotes in medium lacking supplemental
biopterin, indicating the essential nature of this
gene in Leishmania under conditions of limited
pteridine availability.
2. Materials and methods
2.1. Molecular constructs
Three plasmid constructs (pfdhPacG, pGHygG,
pGdhBleGX) were prepared for the targeted re-
placement of the three BT1 alleles in L. dono6ani
strain LSB-51.1 (MHOM:SD:00:Khartoum) and
a fourth (pGGdhNeoG) for introduction of an
episomal copy of BT1. All constructs were grown
in Escherichia coli SURE™ cells (Stratagene) and
plasmid DNA isolated using Promega Wizard or
Qiagen kits.
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2.1.1. pFNeoG
pFNeoG, which contains the neomycin phos-
photransferase (NPT) gene flanked at its 5% and 3%
ends by the ORFE-ORFF and BT1-ORFH inter-
genic regions, respectively, served as the backbone
from which the four transformation constructs
were derived. DNA from clone pB3FL35 [17] was
digested with XbaI to release a 2753-bp fragment,
and religated to produce plasmid pBX3FL8,
which contains the ORFI-ORFb intergenic region
in a pBluescriptII SK (Stratagene) backbone.
The ORFA-ORFB intergenic region was PCR am-
plified from clone pKH6 [14], using primers MR
(5%-aacagctatgaccatg) and B-5orfBr (5%-GCTG-
GaTCcTACAGGAGC), the product digested
with HindIII and BamHI and ligated into
HindIIIBamHI-digested pBX3FL8 DNA to
produce p5B3I. The NPT gene was amplified
from pNEO (Pharmacia) with primers B-5B-
5Neo (5% - taggatccagcaATGATTGAACAAGA-
TGG) and BmN-3Neo (5%-accagcattcgcggc-
CGCTCAGAAGAACTCG), the product di-
gested with BamHI and BsmI, then ligated into
BamHIBsmI-digested p5B3I DNA to produce
clone pBNeoI. The ORFE-ORFF intergenic re-
gion was amplified from clone pCK1 [15],
with primers Hd5EFi (5%-GAGGAGACCACA-
GaAGCTTCTCTC) and B3EFi (5%-ATGGatc-
CTGACGAGAAGAATG), the product digested
with HindIII and BamHI, and ligated into
HindIIIBamHI-digested pBNeoI DNA to pro-
duce pFNeoI. The BT1-ORFH intergenic region
was amplified from pK22 [12] with primers
N5GHi (5%-AGGTGATGGcGGCCGCACTC)
and St3GHi (5%-tcCCGCgGCACCGAAGA-
GAGC), the product digested with NotI and SstII
and ligated into NotISstII-digested pFNeoI
DNA, replacing the ORFI-ORFb intergenic re-
gion with BT1-ORFH intergenic sequence, to gen-
erate pFNeoG.
2.1.2. PfdhPacG
PfdhPacG, which contains the puromycin N-
acetyl transferase (PAC) gene flanked by the 5%
and 3% intergenic regions from the Leishmania
major dihydrofolate reductase:thymidylate syn-
thetase (DHFR-TS) gene, all bounded by the
ORFE-ORFF and BT1-ORFH intergenic regions,
was used to replace one allele of both ORFF and
BT1 on chr35. pFNeoG DNA was digested with
NotI and the ends filled with T4 DNA polymerase
(Gibco BRL). It was then digested with BamHI to
release the NPT gene and the ends partially filled
with dATP and dGTP using the Klenow fragment
of E. coli DNA polymerase (Gibco BRL). A
DNA fragment containing the PAC gene bounded
by the L. major DHFR-TS flanking regions, was
obtained from pX63PAC DNA [18] by digestion
with BglII, followed by complete filling of the
digested ends, and XhoI digestion, followed by
partially filling with dTTP and dCTP. This frag-
ment was ligated with the larger fragment result-
ing from digestion of pFNeoG DNA with NotI,
followed by complete filling, and BamHI, fol-
lowed by partial filling with dGTP and dATP, to
obtain pGdhPacG.
2.1.3. pGHygG
pGHygG, which contains the hygromycin B
phosphotransferase (HYG) gene flanked by the
ORFF-BT1 and BT1-ORFH intergenic regions,
was used to replace the second allele of BT1 on
chr35. The ORFF-BT1 intergenic region was am-
plified from pK27 [12] with primers MF (5%-
gtaaaacgacggccagt) and B3FGi (5%-gcggat-
CCTGGTATGATGGC), and the product di-
gested with KpnI and BamHI. This fragment was
then ligated with pFNeoG DNA which was di-
gested with KpnI and BamHI (to remove the
ORFE-ORFF intergenic region) to produce pG-
NeoG. The NPT gene was removed from pG-
NeoG by NotI digestion and complete filling of
the digested ends, followed by BamHI digestion.
The larger fragment from this digestion was lig-
ated with a fragment containing the HYG gene
obtained by BamHINaeI digestion of pTSA-
HYG2 [19] to produce pGHygG.
2.1.4. pGdhBleGX
pGdhBleGX, which contains the bleomycin:
phleomycin binding protein (BLE) gene bounded
on its 5% side by the ORFF-BT1 intergenic region
and on its 3% side by the BT1-x 3% flanking se-
quence [17], was used to replace the BT1 allele on
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chr27. The NPT gene with DHFR-TS flanking
sequences was amplified from pX63Neo [20] with
primers 5%dhfrS (5%gcGgAtccCACCCCACCCCT-
GCATTC) and 3%dhfrAS (5%-AggcGGccGcGC-
TACGGT) and the product digested with BamHI
and NotI. This fragment was then ligated with
BamHINotI-digested pGNeoG DNA replacing
the existing NPT gene (lacking the DHFR-TS
flanking sequences) to produce pGdhNeoG. The
BT1-x 3% flanking sequence in clone pNE78 [17]
was amplified using primers N5GHi (5%-AGGT-
GATGGcGGCCGCACTC) and St3X (5%-atC-
CGCGg6 CGCTCCGTG) and the product digested
with NotI and SstII. The BT1-ORFH intergenic
region from pGdhNeoG was removed by diges-
tion with NotI and SstII and replaced by ligation
with the BT1-x fragment above to obtain pGdh-
NeoGX. The BLE gene was amplified from
pUT333 (Cayla) with primers 5%ble (5%-gacgctcga-
gaggcctATGGGCGAAATGACCGACCA) and
3%bleEcXb (5%-gcgggcgatatctagACTCATGAGAT-
GCCTGCAAGC) and the product digested with
XhoI, followed by complete filling of digested
ends, then EcoRV. pGdhNeoGX DNA was di-
gested with SpeI to remove the NPT gene, the
ends completely filled using Klenow and dephos-
phorylated using Calf Intestinal Alkaline Phos-
phatase (Gibco:BRL), and then ligated with the
BLE fragment above. The resultant clones were
screened to obtain one (pGdhbleGX) in which the
BLE gene was in the appropriate orientation.
2.1.5. pGGdhNeoG
The episomal rescue construct, pGGdhNeoG,
contains an intact copy of BT1 along with its
wild-type 5% and 3% flanking sequences, upstream
of the NPT gene bounded by DHFR-TS flanking
sequences, and second copy of the BT1-ORFH
intergenic region. A 3250-bp fragment containing
BT1 and its 5% and 3% flanking sequences was
obtained by digestion of pS85 [12] DNA with
BglII, DraI and XhoI. pGdhNeoG DNA by di-
gested with BamHI, the ends completely filled,
and further digested with BglII to remove a 438-
bp fragment containing the ORFF-BT1 intergenic
region. The remaining fragment from pGdhNeoG
(containing the NPT gene and the BT1-ORFH
intergenic region) was then ligated with the BT1-
containing fragment from pS85 to obtain
pGGdhNeoG.
2.2. Parasite culture and transformation
All parasite cell lines used in this study were
derived from LSB-51.1, except for a clonal line of
L. dono6ani strain D1700, which was kindly pro-
vided by Dr Buddy Ullman (OHSU). Promastig-
otes stages were grown at 24°C in AM medium as
previously described [17], except where otherwise
noted. Methods for cell electroporation and cell
plating have been described previously [21] and
were utilized with only minor changes. Briefly,
Leishmania promastigotes were grown to late-log
phase, washed in phosphate-buffer saline solution
(PBS, 10 mM NaH2PO4, 10 mM Na2HPO4, 145
mM NaCl), followed by electroporation (EP)
buffer (21 mM HEPES, 137 mM NaCl, 5 mM
KCl, 0.7 mM NaH2PO4, 6 mM glucose, pH7.4),
and suspended in EP buffer at 2108 cells:ml.
Purified plasmid DNA from the BT1 replacement
constructs above was linearized (with HindIII
SpeI for pFdhPacG, BssHII for pGHygG, and
KpnISstII for pGdhBleGX) before addition of
5 mg to 0.4 ml of the cell solution in electropora-
tion cuvettes (BTX). For the episomal BT1 rescue,
cells were incubated on ice for 10 min with 50 mg
of undigested (circular) pGGdhNeoG DNA, be-
fore electroporation using a BTX Electro Cell
Manipulator® 600 with settings of 480 V, 13 V,
and 500 mF. Cells were cultured for 18 h in AM
medium before spreading on plates containing
0.7% Seaplaque GTG agarose (FMC BioProd-
ucts) in AM media with 20–80 mg ml1 neomycin
(G418), 25 mg ml1 puromycin, 20 mg ml1 hy-
gromycin, or 12.5 mg ml1 phleomycin to isolate
single colonies. For transformations using
pGdhBleGX, the medium was supplemented with
7.5 mM each of biopterin, dihydrobiopterin, fo-
late, and dihydrofolate. Biopterin (Sigma) and
dihydrobiopterin (Schircks Laboratories, Jona,
Switzerland) stock solutions were made in 40 mM
Hepes, pH 7.4, 5 mM DTT while folate and
dihydrofolate were made in distilled H2O. After
confirmation by Southern blot analysis that re-
combinant Leishmania clones were of the appro-
priate genotype (see below), they were maintained
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in AM media without antibiotic selection, except
those containing the episomal construct pGGdh-
NeoG which were maintained in 40–88 mg ml1
neomycin. For comparison of growth rates be-
tween cell lines, stationary phase promastigotes
were inoculated at a density of 2106 cells ml1
into fresh Minimum Essential Medium with a
modification (a-MEM) [22], with or without sup-
plementation with biopterin and folate (7.5 mM
each of biopterin, dihydrobiopterin, folate and
dihydrofolate). Cell densities of duplicate cultures
were determined at 24-h intervals and doubling
times calculated by regression analysis using an
exponential curve fit (SigmaPlot).
2.3. Southern and Northern blot analysis
Chromosome-sized DNA was prepared in
agarose blocks, separated by clamped homoge-
nous electric field electrophoresis (CHEF) using a
Bio-Rad CHEF Mapper, and transferred to Ny-
lon membranes (GeneScreen, NEN LifeScience)
as previously described [17]. Genomic DNA was
extracted from Leishmania using a method
adapted from Bellofatto and Cross [23]. Late log-
phase promastigotes were collected by centrifuga-
tion, washed in PBSG (PBS with 0.2% glucose),
resuspended in EA solution (0.01 M Tris, pH 8.0,
0.25 M NaCl, 0.005% NP-40) and incubated 5
min at room temperature. Lysates were cen-
trifuged and the pellets resuspended in EB solu-
tion (0.01 M Tris, pH 8, 0.01 M NaCl, 0.01 M
EDTA, 0.5% SDS, 50 mg ml1 proteinase K) and
incubated on ice for 5 min. The DNA solution
was extracted sequentially with equal volumes of
phenol:chloroform:isoamyl alcohol (25:24:1) and
chloroform:isoamyl alcohol (24:1), then precipi-
tated at 20°C with 0.3 M sodium acetate and
two volumes of 95% ethanol. The DNA pellet
was collected by centrifugation and resuspended
in TE (10 mM Tris, pH 8.0, 1 mM EDTA). DNA
was digested with restriction enzymes and sepa-
rated by conventional agarose gel electrophoresis
or field inversion gel electrophoresis (FIGE),
stained with ethidium bromide, and transferred to
nylon membranes as described previously [17].
Total RNA was extracted from Leishmania using
an acid guanidinium-phenol-chloroform method,
then 10 mg aliquots were separated on MOPS:
formaldehyde agarose gels and transferred to ny-
lon filters as described previously [12,17]. Nucleic
acids were cross-linked to the filters with a
Stratalinker UV-crosslinker (Stratagene) accord-
ing to the manufacturer’s instructions. Filters
were hybridized with [a-32P]dATP-labeled probes
prepared from gel-isolated DNA fragments using
the Random Primers DNA labeling System
(Gibco:BRL). The BT1 probe was a 375-bp frag-
ment from BamHINotI-digested pK27 [12].
The 577-bp a-tubulin probe was obtained by
PCR amplification of genomic DNA using
primers 5%Ktubg (5%-atgggtaccGCTATCTG-
CATCCACATC) and 3%Xtubg (5%-ccgctc-
gagACAGCACGCAGTTGTAC). Hybridization
was carried out for 3 h at 65°C in Rapid Hybe
solution (Amersham Life Science). The filters
were washed twice in 2SSC (0.3 M NaCl, 0.03
M sodium citrate, pH 7.0), 0.1% SDS for 5 min
at room temperature followed by two washes in
0.1SSC, 0.1% SDS for 20 min at 65°C.
2.4. Expression of recombinant BT1 and Western
blot analysis
The region encoding the C-terminal 63 amino
acids of BT1 was amplified from clone pS85 [12]
using primers LD1-G31 (5%-CTgaaTTCGAC-
CTCCTCATTTTG) and 3EorfG (5%-cgaattC-
TAGCTGTCCCGCTTC). The resulting product
(488 bp) was digested with BclI and EcoRI, lig-
ated into BamHIEcoRI-digested pRSETC (In-
vitrogen), and transformed into E. coli SURE™
cells (Stratagene) to produce clone pSETCG7B.
Plasmid DNA from this clone was transformed
into BL21 cells (Novagen) and induced with
IPTG (isopropyl-b-D-thiogalactopyranoside) to
express recombinant protein. Recombinant
pSETCG7b protein (10.5 kDa) was purified using
ProBond™ Metal-Binding Resin (Invitrogen) ac-
cording to the manufacturer’s instructions.
Protein was eluted from the column in DBB
buffer pH 4.0 supplied with the kit, dialyzed in
PBS to remove urea, and concentrated with a
Centricon 3 concentrator (Micon). Purified
protein (300 mg) was mixed with equal volume
of incomplete Freund’s adjuvant plus 100 mg mu-
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ramyldipeptide (MDP) and injected subcuta-
neously into a New Zealand White rabbit. The
rabbit was boosted with the same amount of
recombinant protein:adjuvant mixture six addi-
tional times at 2-week intervals after which serum
was obtained at sacrifice.
Leishmania promastigotes were grown to late
log-phase in M199 medium (Gibco:BRL) supple-
mented with 100 units ml1 penicillin, 100 mg
ml1 streptomycin, and 10% heat inactivated fe-
tal bovine serum (Biological Industries Israel);
collected by centrifugation; washed with PBSG;
and resuspended in SDS-PAGE buffer (0.15 M
Tris, pH 6.8, 4.0% SDS, 20% glycerol, 0.06%
bromophenol blue, 1.4 M 2-mercaptoethanol) to a
concentration of 5109 cells per ml. Protein sam-
ples representing 107 cells were boiled and sepa-
rated on a 10% polyacrylamide-SDS gel and
transferred to a nitrocellulose membrane by stan-
dard Western blotting methods [24]. Membranes
were washed three times for 10 min each in PBS
with 0.1% Tween-20 and blocked for 1 h at room
temperature in PBS plus 0.1% Tween-20 and 5%
low-fat milk. The membranes were washed again,
incubated for 1 h at room temperature in 1:200
dilution of rabbit antiserum in PBS with 0.1%
Tween-20 before being washed again as described
above. The membrane was incubated in 1:8000
dilution of protein A-horseradish peroxidase,
washed again, and exposed to ECL System detec-
tion solution (Amersham) according to the manu-
facturer’s instruction. Bound antibodies were
visualized by autoradiography.
2.5. Biopterin uptake assays
Biopterin uptake studies were carried out essen-
tially as described elsewhere [25,26]. Briefly, pro-
mastigotes were grown to mid-log phase
(3–6106 cells:ml) in M199 medium [21], har-
vested by centrifugation, washed twice with M199
medium lacking folate and thymidine and con-
taining 0.66% bovine serum albumin (BSA;
fdM199, Gibco:BRL), resuspended in fdM199 at
3106 cells:ml and incubated overnight. Cells
were then harvested, washed once with transport
medium (fdM199 lacking BSA) and resuspended
at 5108 cells:ml in transport medium. The cell
suspension (100 ml) was mixed with 100 ml HPLC-
purified [3H]-biopterin (52 mCi:mmol, batch 127-
276-0129, Moravek) [25] on top of a 100 ml
dibutyl phthalate cushion in a microfuge tube to a
final substrate concentration of 200 mM. Tripli-
cate samples were incubated for 10 min at either
23 or 4°C, and the reaction terminated by spin-
ning the cells through the cushion at 16 000g
for 30 s. The aqueous layer was removed and the
cushion washed twice with Hank’s Buffered Salt
Solution. The cell pellet was recovered, lysed with
100 ml 1% Triton X-100 and counted in Scinti-
verse II scintillation fluid (Fisher). Biopterin up-
take due to active transport was determined by
subtracting values obtained at 4°C from those
obtained at 23°C.
3. Results
3.1. Targeted gene replacement of BT1
L. dono6ani strain LSB-51.1 (51.1) used in this
study contains three copies of BT1: one allele in
the LD1 locus on each homolog of chr35 and a
single copy in the rRNA locus on one chr27
homolog [17]. Thus, the genotype of 51.1 wild
type (WT) cells is BT1:BT1chr35 BT1chr27 and
production of BT1 null mutants requires three
successive rounds of targeted gene replacement
(Table 1). Electroporation of WT cells with the
construct pFdhPacG and selection with
puromycin yielded transformants in which one
allele of both ORFF and BT1 on chr35 was
replaced with the PAC gene. Southern blot analy-
sis of genomic DNA from a resultant cloned cell
line (SKOD35) using probes for BT1 (Fig. 1, lane
2) and PAC (data not shown) confirmed one BT1
allele on chr35 was replaced with the PAC gene.
Thus, this cell line retains the other BT1 allele on
chr35 and other copy on chr27 (i.e. the genotype
is DorffDbt1::PAC:BT1chr35 BT1chr27).
The remaining BT1 allele on chr35 in SKOD35
cells was replaced by electroporation with con-
struct pGHygG and isolation of single colonies
following hygromycin selection (Table 1). Ge-
nomic Southern analyses using probes for BT1
(Fig. 1, lane 4) and HYG (data not shown) confi-
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Table 1
Description of recombinant Leishmania cell lines
SKOD35Cell line SKOD27WT DKOD35 TKO TKO-rescue
Constructa
X X XPfdhPacG X
X XPGHygG X
PgdhbleGX X X X
PGGdhNeoG X
BT1 copiesb
1 2chr35 2
1 11chr27
Episomal \1c
a Cells were electroporated with these constructs, as described in the text.
b Number of copies of BT1 per diploid genome.
c Copy number was not determined accurately.
rmed that the second allele of BT1 on chr35 was
replaced with HYG. Thus this cell line, termed
DKOD35, lacked both alleles of BT1 on chr35,
but retained a copy of BT1 on chr27 (i.e. the
genotype is DorffDbt1::PAC:Dbt1::HYG chr35
BT1chr27). BT1 null mutants were produced by
replacing the remaining copy of BT1 by electropo-
ration of DKOD35 with construct pGdhBleGX
and selection of single colonies on phleomycin
plates (Table 1). Initial attempts to isolate null
mutants were unsuccessful until the medium was
supplemented with 7.5 mM each of biopterin, di-
hydrobiopterin, folate, and dihydrofolate. South-
ern analyses of the resulting cell line, termed
TKO, confirmed that it lacked all three copies of
BT1 (Fig. 1, lane 5), having replaced the copy on
chr27 with the BLE gene (data not shown). Thus,
the genotype of the null mutant (TKO) is
DorffDbt1::PAC:Dbt1::HYG chr35 Dbt1::BLE chr27.
As a control, a second single knockout mutant
was produced by electroporation of WT cells with
construct pGdhBleGX and selection on
phleomycin plates. In the resulting cell line,
termed SKOD27, both copies of BT1 on chr35
were retained, but the copy of BT1 on chr27 was
replaced by the BLE gene (Fig. 1, lane 3 and data
not shown). Thus, the genotype of this cell line is
BT1:BT1chr35 Dbt1::BLE chr27.
Finally, to assess whether any phenotypic dif-
ferences observed in the BT1 null mutants were
solely due to the absence of BT1, rather than
unanticipated genetic changes, TKO cells were
electroporated with circular DNA from the con-
Fig. 1. Sequential gene replacement of BT1 in L. dono6ani
LSB-51.1. Genomic DNA (10 mg) from wild type (WT) and
mutant (SKOD35, SKOD27, DKOD35, and TKO) was di-
gested with BglII and Southern blots probed with an BT1-spe-
cific probe (derived from pK27). The 3.7-kb band is derived
from the copies of BT1 on chr35, while the 6.8-kb band is
derived from the copy on chr27, as indicated to the right of the
panel. The molecular size markers (Gibco:BRL) are shown to
the left in kb.
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Fig. 2. Northern blot analysis of BT1 mutants. Total cellular
RNA (10 mg) from the cells indicated was separated by
agarose gel electrophoresis and probed with the BT1-specific
probe (panel A). Hybridization of the same blot with a tubulin
probe (panel B) confirmed equal loading of RNA in each lane.
The chromosomal origin of the 2.8- and 3.5-kb BT1 tran-
scripts are indicated to the right of panel A. Molecular size
markers (Gibco:BRL) are shown to the left in kb.
cellular RNA was extracted from WT cells and
the BT1 deletion mutants, separated by gel elec-
trophoresis and hybridized with a BT1-specific
probe (Fig. 2). The pattern of steady state BT1
mRNA abundance largely reflected the genotype
of each cell line. In WT, an abundant 2.8 kb
transcript and a less abundant 3.5 kb transcript
are detected, corresponding to the mature BT1
transcripts from chr27 and chr35, respectively
[17]. This interpretation is confirmed by the re-
sults from the other cell lines. The 3.5-kb tran-
script is absent in DKOD35 (which lacks both
copies of BT1 on chr35), indicating that this
transcript is derived from chr35. Conversely, the
2.8-kb transcripts and several additional tran-
scripts of 4, 9 and greater than 10 kb are no
longer present in SKOD27, which lacks BT1 on
chr27, indicating their origin from this chromo-
some in WT. The larger transcripts represent pre-
cursors of the BT1 transcript from the BT1:rRNA
locus on chr27 [17]. Interestingly, the abundance
of the 3.5-kb BT1 transcript is elevated in
SKOD27, suggesting the existence of regulatory
systems controlling mRNA abundance. Neverthe-
less, total abundance of BT1 mRNA is substan-
tially decreased in SKOD27. As expected, no
detectable BT1 mRNAs are detected in TKO
confirming the absence of BT1 expression in this
null mutant.
BT1 is predicted to encode a 627-amino acid
protein of 68.9 kDa containing 12 potential mem-
brane-spanning domains [16]. Attempts to express
full-length recombinant BT1 fusion proteins in
bacterial expression systems were unsuccessful,
presumably due to its hydrophobic nature. How-
ever, we were able to express the C-terminal 63
amino acids of BT1 fused to an N-terminal His-
Tag and raise rabbit polyclonal antisera. Western
blot analysis using these antibodies detects a
protein with an apparent size of 45 kDa in all
cell lines, except the null mutant TKO (Fig. 3).
Similar results were obtained by immunoprecipi-
tation (data not shown). Anomalous migration is
not unusual for membrane proteins [27], suggest-
ing that the 45-kDa protein does represent the
BT1 protein product.
struct pGGdhNeoG and selected on plates con-
taining neomycin. The resulting cloned cell line,
termed TKO-rescue, contain a copy of BT1 (and
NEO) on an extrachromosomal element (Table
1). TKO-rescue cells (genotype DorffDBT1::PAC:
Dorfg::HYG chr35 Dorfg::BLE chr27 [pX NEO BT1])
were grown in media supplemented with
neomycin to maintain a high copy number of the
plasmid.
3.2. BT1 expression in mutant cell lines
BT1 expression at the RNA level was investi-
gated by Northern blot analysis (Fig. 2). Total
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3.3. BT1 encodes a biopterin transporter
Previously studies using homologous and het-
erologous expression systems indicated that
ORFG:BT1 encoded a biopterin:folate trans-
porter (Moore and Beverley, abstract 107, Woods
Hole Molecular Parasitology Meeting, 1996, Cun-
ningham et al., abstract 236, Woods Hole Molec-
ular Parasitology Meeting, 1997). The inability to
obtain BT1 null mutants in the absence of
biopterin and folate supplementation of growth
medium (Section 3.1) was consistent with this
finding. In order to assess directly the role of BT1
in pteridine transport, uptake of [3H]-biopterin
was determined in wild type 51.1 (WT) and the
transgenic BT1 mutants described above (Fig. 4).
WT cells showed the highest biopterin transport
levels at 463.0916.0 pmol min1 (109cells)1,
after correction for passive diffusion (i.e.
biopterin uptake at 4°C). The levels in the null
mutant (TKO) were just above background at
7.994.2 pmol min1 (109cells)1. Reintroduc-
tion of BT1 into TKO on an episomal plasmid
Fig. 4. Biopterin transport in BT1 mutant cell-lines. Active
biopterin transport (in pmol min1 per 109 cells) was deter-
mined by subtracting the amount accumulated at 4°C from
that accumulated at 23°C. All values are the means of tripli-
cate assays and the error bars represent one standard devia-
tion.
(TKO-rescue) led to an increase in biopterin up-
take to 47.990.7 pmol min1 (109cells)1. Thus,
BT1 encodes a biopterin transporter and has been
renamed BT1 (Biopterin Transporter 1). The
biopterin uptake level in SKOD35 parasites was
452.1916.7 pmol min1 (109cells)1, indicating
that biopterin transport was unaffected by the
loss of a single chr35 allele of BT1. Loss of the
second chr35 BT1 allele in DKOD35 cells caused
a modest, but measurable, reduction in biopterin
uptake to 383.3914.4 pmol min1 (109 cells)1.
In contrast, deletion of the single BT1 gene from
chr27 in SKOD27 cells led to a dramatic reduction
in biopterin uptake to 48.593.0 pmol min1
(109cells)1. This level is similar to the value of
53.192.8 pmol min1 (109cells)1 obtained with
another strain (D1700) of L. dono6ani, which does
not contain any amplification of BT1.
Comparison of the growth rates of these cells
lines in the presence of supplemental biopterin
and folate showed doubling times of 50, 53, 71
and 137 h for WT, SKOD35, DKOD35, and
Fig. 3. Western blot analysis of BT1 mutants. Protein samples
representing 107 Leishmania cells from the cell-lines indicated
were separated by SDS-PAGE and probed with rabbit anti-
serum against recombinant BT1 protein. Bound antibodies
were detected using the ECL System (Amersham). The BT1
protein is indicated by the arrow to the right. Molecular
weight markers (Pharmacia) are shown to the left in kDa.
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TKO, respectively. In the absence of
supplemental biopterin and folate, these values
increased to 77, 91, 131 and greater than 186
h, respectively. The TKO cell line died after 1–2
weeks in this medium, and could be maintained
only in medium containing supplemental
biopterin and folate. Thus, deletion of BT1 genes
has a substantial effect on growth rate, especially
in the absence of supplemental biopterin and
folate.
4. Discussion
The multigenic LD1 locus that is near one end
of chr35 is frequently amplified in several species
of Leishmania [10,12,13]. While the region that is
amplified varies among strains, two genes, ORFF
and BT1, are invariably part of the amplification
unit [13], suggesting that one or both have impor-
tant roles in the parasite. Transfectants containing
cosmids or plasmids expressing BT1 functionally
complemented a methotrexate-resistant L. dono-
6ani mutant deficient in folate transport (Moore
and Beverley, abstract 107, Woods Hole Molecu-
lar Parasitology Meeting, 1996). These lines
showed elevated uptake of both biopterin and
folate, suggesting that BT1 encoded a biopterin:
folate transporter. Analogous results were also
obtained in L. tarentolae [28]. Subsequent studies
expressing L. dono6ani BT1 mRNA in Xenopus
oocytes (Cunningham et al., abstract 236, Woods
Hole Molecular Parasitology Meeting, 1997)
confirmed that BT1 encodes a biopterin trans-
porter. Here, we use a reverse genetic approach to
show that BT1 encodes the primary transporter of
biopterin in Leishmania. Analysis of single, dou-
ble and triple (null) knockout mutants of BT1
derived from L. dono6ani 51.1 (which contains an
allele of BT1 on each homolog of chr35 and a
single copy in one rRNA locus on chr27) revealed
a direct correlation between expression levels of
the BT1 gene product and active transport of
biopterin into the cells. Wild-type 51.1 cells (WT)
and mutants with an intact copy of BT1 on chr27
(SKOD35 and DKOD35) showed substantially
higher (approx. seven to nine-fold) biopterin up-
take activity than those with only the chr35 alleles
(L. dono6ani D1700, SKOD27), confirming that
the increased BT1 expression level due to the
transcription of chr27 copy by the RNA poly-
merase I [17] has phenotypic consequences. TKO-
rescue cells, which contain BT1 only on an
episomal plasmid, showed biopterin transport lev-
els similar to cells expressing only the chr35 copies
of BT1.
The exact role of biopterin in Leishmania
metabolism remains unresolved [29]. Previous
studies have demonstrated its role in hydroxyla-
tion of phenylalanine and tyrosine, cleavage of
ether-linked lipids, and biosynthesis of nitric ox-
ide in other organisms [30]. However, phenylala-
nine hydroxylase activity has not been detected in
trypanosomatids [31], and ether-linked lipid cleav-
age in Leishmania appears to use NADPH as a
co-factor [32]. Biopterin is closely linked to the
folate biosynthesis, since biopterin can compen-
sate for folate deficiency in culture medium [33–
36]. Furthermore, [3H]-biopterin is converted into
tetrahydrofolates in L. dono6ani [35]. However,
biopterin is thought to have essential functions
independent of the folate pathway [29], since nei-
ther folate nor dihydrofolate can rescue null mu-
tants of pteridine reductase (PTR1), the enzyme
which catalyzes biopterin reduction [37]. In addi-
tion, dihydropteridine reductase (DHPR), which
is involved in regeneration of tetrahydrobiopterin
from quinonoid tetrahydrobiopterin, is expresed
in Leishmania [37] and alteration in expression of
PTR1 affects the oxidant sensitivity of Leishmania
[29]. Thus, biopterin plays a critical, yet un-
defined, metabolic role in Leishmania.
Since Leishmania are auxotrophic for pteridines
and must acquire them from their host uptake of
biopterin would seem critical for the parasites’
survival. The role of BT1 in this uptake is sup-
ported by the inability of null mutants (TKO) to
survive long-term in culture without biopterin and
folate supplementation. In contrast, wild-type
parasites are able to grow under these conditions
of limited pterin availability. Moreover, we were
unable to obtain null mutants by targeted gene
replacement in standard growth medium without
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added biopterin and folate (Section 3.1). All re-
combinants from these transformations selected
without pteridine supplementation contained am-
plified copies of the BT1 gene in addition to
integration of the knockout construct at the in-
tended site (data not shown). This is similar to
results obtained by others when attempting to
create null mutants of essential loci in Leishmania
[38–40]. Thus, uptake of biopterin by BT1 ap-
pears critical for cell survival at physiological
concentrations of biopterin. The BT1 null mu-
tants (TKO), showed significantly slower growth
as promastigotes, even in the presence of supple-
mental biopterin and folate, suggesting that their
ability to grow in this medium is due to uptake of
biopterin via passive diffusion or a secondary
(and lower-affinity) transporter. Conversely, am-
plification and over-expression of BT1 confers a
significant growth advantage in both naturally-
isolated (Dole et al., manuscript in preparation)
and recombinant (Moore and Beverley, abstract
107, Woods Hole Molecular Parasitology Meet-
ing, 1996, Cunningham et al., abstract 236,
Woods Hole Molecular Parasitology Meeting,
1997) cell lines, suggesting that this may be the
selective pressure for the frequent amplification of
LD1 seen in 15% of Leishmania isolates
[2,5,10].
Targeting the folate pathway with chemothera-
peutic agents such as methotrexate has been suc-
cessful in other organisms but proves ineffective
in Leishmania. DHFR-TS, the enzyme involved in
the reduction of folate to tetrahydrofolate, is in-
hibited by methotrexate; however, Leishmania is
also able to carry out these reactions using PTR1,
which is resistant to methotrexate inhibition [37].
Thus, PTR1 acts as an alternate pathway for
folate reduction; and indeed, methotrexate resis-
tance results from PTR1 gene amplification
[29,37]. Recent attempts to inhibit the folate path-
way by targeting PTR1 and DHFR-TS with in-
hibitors of both enzymes appear promising [41].
Since BT1 is essential for parasite survival, it
provides an attractive candidate for development
of novel anti-leishmanial therapeutic agents that
inhibit the folate pathway at the site of pteridine
entry. This approach may be especially effective if
combined with agents targeting the folate trans-
porter and:or other elements in the pathway.
Given the ability of the Leishmania genome to
readily duplicate and amplify genes and to de-
velop drug resistance by compensating with alter-
native pathways, it is likely that a multi-targeted
approach will be needed to create effective anti-
leishmanial agents.
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